Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2020-08-06 Report Publication Anno…
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
The company's financial statements for the second quarter 2020 reported abroad
Report Publication Announcement Classification · 95% confidence The document is very short (364 characters) and states that the company's financial statements for the second quarter 2020 have been reported abroad. It does not contain any actual financial data or detailed analysis, but rather appears to be a brief notification or announcement. According to the 'MENU VS MEAL' rule, such short notices that mention a report but do not include it should be classified as Report Publication Announcement (RPA).
2020-08-06 Hebrew (modern)
Regulatory Filings 2020
Regulatory Filings
2020-07-06 English
prospectus dated July 2, 2020 relates to the resale of ADS
Capital/Financing Update Classification · 95% confidence The document explicitly uses the term "prospectus" multiple times in the title, headers, and body. It details the resale of securities (ADSs and ordinary shares) by selling shareholders, references the SEC, discusses risk factors, and includes a detailed Table of Contents typical of a registration statement filing. This structure and content strongly indicate a registration statement filed with the SEC to register securities for resale, which is typically filed on Form S-1 or, if it relates to resale of securities previously registered, often takes the form of a resale prospectus, which falls under the general category of capital/financing activities or a specific registration filing. Given the options, the document is a prospectus related to the offering and resale of shares, which is a form of capital/financing activity. However, the most specific SEC filing type that covers the registration of securities for sale is often associated with the initial offering or resale registration. Since the document is a prospectus detailing the offering of securities for resale, it is most closely aligned with 'Capital/Financing Update' (CAP) as it details the structure and terms of the securities being offered/resold, or potentially a registration statement filing. Given the options, 'CAP' (Capital/Financing Update) is the best fit for a document detailing the terms of a security offering/resale, as opposed to a periodic report (10-K, IR) or a general announcement (RPA, RNS). It is not a DEF 14A (Remuneration) or a DVA (Voting Results). It is a formal document detailing the terms of a security offering/resale.
2020-07-05 English
prospectus dated July 2, 2020 relates to the resale of ADS
Report Publication Announcement Classification · 98% confidence The document is a filing notification from BIOLINE RX LTD, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states, "Attached hereto is a report on *[Hebrew text]*" followed by a filename "*424B3_isa.pdf*". The reference to '424B3' strongly suggests a US SEC filing related to a registration statement (often for securities offerings). Since this document is short (1838 chars) and its primary function is to announce the attachment/publication of another report (the 424B3 PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K, IR, or ER.
2020-07-05 English
424B3
Regulatory Filings
2020-07-02 English
Regulatory Filings 2020
Regulatory Filings
2020-07-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.